Celgosivir

Drug Profile

Celgosivir

Alternative Names: 6-O-Butanoylcastanospermine; 60P 001; BuCast™; celgosivir hydrochloride; MBI-3253; MDL 28574; MDL 28574A; MX-3253; VIR 222

Latest Information Update: 23 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer 60 Degrees Pharmaceuticals Australia; Carrus Capital Corporation; Duke-NUS Graduate Medical School Singapore; Singapore General Hospital
  • Class Antivirals; Indolizines; Small molecules
  • Mechanism of Action Alpha-glucosidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Dengue
  • Discontinued Hepatitis C; HIV infections

Most Recent Events

  • 23 Jan 2018 Celgosivir is still in phase I/II trials for Dengue in Singapore (60 Degree Pharmaceuticals pipeline, January 2018)
  • 11 Dec 2015 Celgosivir licensed to Knight Therapeutics in Canada, Israel and Russia
  • 19 Aug 2011 Discontinued - Phase-II for Hepatitis C in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top